SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Kalaris Therapeutics Inc KLRS NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Kalaris Therapeutics Inc (KLRS) is a Biotechnology company in the Healthcare sector, currently trading at $5.87. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is KLRS = $21 (+257.8% upside).

Valuation: KLRS trades at a trailing Price-to-Earnings (P/E) of -3.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.09.

Net income is $43M (loss), growing at -89.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $1M against $79M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 12.23 (strong liquidity). Debt-to-assets is 1.2%. Total assets: $122M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

KLRS SharesGrow Score Overview

62/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — KLRS

KLRS trades at a trailing Price-to-Earnings (P/E) of -3.2 (S&P 500 average ~25). Forward PEG 0.09 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $21, implying +257.8% from the current price $6. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

KLRS: +0%/yr revenue is, -89.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet KLRS: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 12.23 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

KLRS: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 0 analysts rate KLRS as buy. Analyst consensus target is $21 (+257.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range2.14-11.88

Volume166.32K

Avg Volume (30D)63.15K

Market Cap$109.78M

Beta (1Y)-0.14

Share Statistics

EPS (TTM)-2.85

Shares Outstanding$15.27M

IPO Date2020-07-30

Employees14

CEOAndrew Oxtoby

Financial Highlights & Ratios

Gross Profit$-13K

EBITDA$-46.14M

Net Income$-43.44M

Operating Income$-46.15M

Total Cash$117.98M

Total Debt$1.45M

Net Debt$-96.61M

Total Assets$121.74M

Price / Earnings (P/E)-2.1

Analyst Forecast

1Y Price Target$21.00

Target High$23.00

Target Low$19.00

Upside+257.8%

Price Target Summary

Company Info

CountryUS

ExchangeNASDAQ Global Market

CurrencyUSD

ISINUS4829291065

Price Chart

KLRS

Kalaris Therapeutics Inc ↗ · NASDAQ Global Market

Healthcare • Biotechnology

2.14 52WK RANGE 11.88

People Also View

Ovid Therapeutics Inc.

Shattuck Labs, Inc.

Sutro Biopharma, Inc.

Context Therapeutics Inc.

Artiva Biotherapeutics, Inc.

Connect Biopharma Holdings Limited

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message